Take orally with or without food, usually once daily at bedtime to minimize nausea and sleep disturbances. Swallow whole; do not crush, chew, or break.

Fluvoxamine selectively inhibits the reuptake of serotonin (5-HT) into presynaptic neurons, thereby increasing the concentration of serotonin in the synaptic cleft. This leads to enhanced serotonergic neurotransmission, which is believed to be responsible for its antidepressant and anxiolytic effects.

• •Hypersensitivity to fluvoxamine or any component of the formulation.
• •Concomitant use with Monoamine Oxidase Inhibitors (MAOIs) or within 14 days of discontinuing an MAOI (risk of serotonin syndrome).
• •Concomitant use with tizanidine, thioridazine, or pimozide (due to potential for QT prolongation and other severe adverse effects).
• •Co-administration with other serotonergic drugs (e.g., triptans, tricyclic antidepressants, fentanyl, lithium) requires careful monitoring.

Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.

Symptoms of overdose include nausea, vomiting, diarrhea, somnolence, dizziness, tachycardia, bradycardia, hypotension, seizures, and rarely, coma. Management involves symptomatic and supportive measures. There is no specific antidote. Gastric lavage or activated charcoal may be considered if ingested recently.

Pregnancy Category C. Use only if potential benefit justifies potential risk to the fetus. Fluvoxamine is excreted in human milk; avoid during breastfeeding or use with caution after consulting a physician.